Information on EC 2.1.1.6 - catechol O-methyltransferase

New: Word Map on EC 2.1.1.6
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria

EC NUMBER
COMMENTARY hide
2.1.1.6
-
RECOMMENDED NAME
GeneOntology No.
catechol O-methyltransferase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
S-adenosyl-L-methionine + a catechol = S-adenosyl-L-homocysteine + a guaiacol
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
methyl group transfer
-
-
-
-
O-methylation
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
3,5-dimethoxytoluene biosynthesis
-
-
Betalain biosynthesis
-
-
betaxanthin biosynthesis
-
-
dopamine degradation
-
-
L-dopa degradation
-
-
Metabolic pathways
-
-
noradrenaline and adrenaline degradation
-
-
Steroid hormone biosynthesis
-
-
Tyrosine metabolism
-
-
SYSTEMATIC NAME
IUBMB Comments
S-adenosyl-L-methionine:catechol O-methyltransferase
The mammalian enzyme acts more rapidly on catecholamines such as adrenaline or noradrenaline than on catechols.
CAS REGISTRY NUMBER
COMMENTARY hide
9012-25-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
common marmoset
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
African catfish
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
CHO cell line
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
S-COMT
-
-
Manually annotated by BRENDA team
S-COMT
-
-
Manually annotated by BRENDA team
S-COMT
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
-
concerted action of cytosolic sulfotransferase SULT1A3 and COMT in dopamine metabolism
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(+)-catechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
(+)-epicatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
(-)-epicatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
(-)-epigallocatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
(-)-epigallocatechin-3-O-gallate + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
(R)-1,2-dihydroxy-4-[2-(methylamino)butyl]benzene + S-adenosyl-L-methionine
?
show the reaction diagram
-
-
-
-
?
(R)-3,4-dihydroxymethamphetamine + S-adenosyl-L-methionine
?
show the reaction diagram
-
-
-
-
?
(R)-N-ethyl-3,4-dihydroxyamphetamine + S-adenosyl-L-methionine
?
show the reaction diagram
-
-
-
-
?
(S)-1,2-dihydroxy-4-[2-(methylamino)butyl]benzene + S-adenosyl-L-methionine
?
show the reaction diagram
-
-
-
-
?
(S)-3,4-dihydroxymethamphetamine + S-adenosyl-L-methionine
?
show the reaction diagram
-
-
-
-
?
(S)-N-ethyl-3,4-dihydroxyamphetamine + S-adenosyl-L-methionine
?
show the reaction diagram
-
-
-
-
?
1-carboxy-1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
2-hydroxyestradiol 3-methyl ether + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
2-methoxyestradiol + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 2-methoxyestradiol + 2-hydroxy-3-methoxyestradiol
show the reaction diagram
-
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
2-hydroxyestradiol-17beta + S-adenosyl-L-methionine
2-methoxyestradiol-17beta + 2-hydroxyestradiol-17beta methyl ether + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
?
2-hydroxyestrogen + S-adenosyl-L-methionine
2-methoxyestrogen + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
-
?
2-hydroxyestrone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
the production of 2-methoxyestrone in cultures treated with 2-hydroxyestrone is approximately 2fold that of 4-methoxyestrone in cultures treated with 4-hydroxyestrone
-
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
3-hydroxy-4-methoxybenzoic acid + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
4-hydroxy-3-methoxybenzoic acid + S-adenosyl-L-homocysteine
show the reaction diagram
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
3,4-dihydroxymandelic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
3,4-dihydroxyphenylacetic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
3,5-dinitrocatechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
3-hydroxytyramine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-methoxytyramine
show the reaction diagram
-
-
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
(17beta)-estra-1(10),2,4-triene-3,4,17-triol + S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
MCF-10F cells oxidize 4-hydroxyestradiol to estrone (estradiol)-3,4-quinones, which react with DNA to form the depurinating N3Ade and N7Gua adducts
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
4-hydroxyestrogen + S-adenosyl-L-methionine
4-methoxyestrogen + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
-
?
4-hydroxyestrone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
4-nitrocatechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
6,7-dihydroxycoumarin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
adrenaline + S-adenosyl-L-methionine
methanephrine + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
-
?
adrenaline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
aesculetin + S-adenosyl-L-methionine
scopoletin + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
-
?
benzene-1,2-diol + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
show the reaction diagram
caffeic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
catechol + S-adenosyl-L-methionine
guaiacol + S-adenosyl-L-homocysteine
show the reaction diagram
catechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
catecholestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
catecholestrone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
DL-3,4-dihydroxyamphetamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
DL-3,4-dihydroxyephedrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
dobutamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
dopamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyldopamine
show the reaction diagram
-
-
-
-
?
dopamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
show the reaction diagram
epinine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
esculetin + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
show the reaction diagram
-
-
-
-
?
esculetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
fisetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
homoprotocatechuic acid + S-adenosyl-L-methionine
?
show the reaction diagram
-
-
-
-
?
isoetharine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
isoproterenol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
L-dopa + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
show the reaction diagram
L-dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyl-L-dopa
show the reaction diagram
L-Dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyldopa
show the reaction diagram
noradrenaline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
norepinephrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + normetanephrine
show the reaction diagram
p-nitrocatechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
procyanidin dimer B1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
procyanidin dimer B2 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
procyanidin dimer B3 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
procyanidin dimer B4 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
procyanidin dimer B5 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
procyanidin dimer B7 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
procyanidin trimer C1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
protocatechualdehyde + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
protocatechuic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
protocatechuic aldehyde + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
show the reaction diagram
-
17% of the activity with catechol
-
-
?
quercetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
S-adenosyl-L-homocysteine + 4',4''-di-O-methyl epigallocatechin gallate
show the reaction diagram
S-adenosyl-L-methionine + 1,2-dihydroxyphenanthrene
S-adenosyl-L-homocysteine + 1-methoxy-2-hydroxyphenanthrene + 1-methoxy-2-hydroxyphenanthrene
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 1-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 1-hydroxypyrene
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 2,3-dihydroxybenzaldehyde
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 2,3-dihydroxynaphthalene
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 2-(1-thienyl)ethyl-3,4-dihydroxybenzylcyano acetate
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 2-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + 3,4-dihydroxy-L-Phe
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + 3,4-dihydroxyacetophenone
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxybenzoic acid
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxybenzoic acid ethyl ester
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxymandelic acid
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxyphenylacetic acid
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxyphenylglycol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 3-fluorocatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 3-methoxy-5-bromocatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 3-methoxycatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 4-chlorocatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 4-hydroxyequilenin
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 4-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 4-isopropylcatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 4-methylcatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 4-nitrocatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 4-tert-butyl-5-methoxycatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 4-tert-butylcatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 5-hydroxydopamine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 6-hydroxydopa
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + 6-hydroxydopamine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + a catechol
?
show the reaction diagram
S-adenosyl-L-methionine + adrenaline
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + anthrarobin
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + carbidopa
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + catechin
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + catechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + chlorogenic acid
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + dihydrexidine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + dobutamine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + dopamine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + epicatechin
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + epicatechin gallate
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + epigallocatechin gallate
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
show the reaction diagram
S-adenosyl-L-methionine + epigallocatechin gallate
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin-3-gallate
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + epinephrine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + epinephrine
S-adenosyl-L-homocysteine + metanephrine
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + esculetin
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + ethyl-3,4-dihydroxybenzylcyanoacetate
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + fisetin
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + gallic acid
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + isoproterenol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + L-Dopa
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + levodopa
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + methyl gallate
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + noradrenaline
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + normetanephrine
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + pyrene
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + pyrogallol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + quercetin
S-adenosyl-L-homocysteine + ?
show the reaction diagram
S-adenosyl-L-methionine + R-salsolinol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + rosmarinic acid
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + salsoline
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + salsoline-1-carboxylic acid
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + scopoletin
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + SKF38393
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + tetrachlorocatechol
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
salvianolic acid B + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
-
-
-
?
tolcapone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
4-hydroxyestradiol + S-adenosyl-L-methionine
(17beta)-estra-1(10),2,4-triene-3,4,17-triol + S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
MCF-10F cells oxidize 4-hydroxyestradiol to estrone (estradiol)-3,4-quinones, which react with DNA to form the depurinating N3Ade and N7Gua adducts
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
show the reaction diagram
-
in the mammary gland, catechol estrogens are predominately inactivated by catechol-O-methyltransferase. in the isoflavone-induced. The estrogen receptor is involved in the down-regulation of COMT expression
-
-
?
homoprotocatechuic acid + S-adenosyl-L-methionine
?
show the reaction diagram
-
-
-
-
?
S-adenosyl-L-methionine + a catechol
?
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Cd2+
-
can substitute for Mg2+
Co2+
-
Co2+ and Mn2+ most effective in activation
Ni2+
-
can substitute for Mg2+
additional information
-
activity of the enzyme is strongly influenced by the nature of the buffer
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-epicatechin-3-gallate
-
IC50: 0.0002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0003 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin
-
IC50: 0.044 mM with 2-hydroxyestradiol as substrate, IC50: 0.05 nM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin gallate
-
potent inhibitor with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(-)-epigallocatechin gallate-4''-O-glucuronide
-
with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(-)-epigallocatechin gallate-7-O-glucuronide
-
with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(-)-epigallocatechin-3-gallate
(-)-epigallocatechin-3-gallate-3''-O-glucuronide
-
IC50: 0.002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0025 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-gallate-3'-O-glucuronide
-
IC50: 0.0018 mM with 2-hydroxyestradiol as substrate, IC50: 0.0023 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-gallate-4''-O-glucuronide
-
IC50: 0.0025 mM with 2-hydroxyestradiol as substrate, IC50: 0.004 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-gallate-7-O-glucuronide
-
IC50: 600 nM with 2-hydroxyestradiol as substrate, IC50: 800 nM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-O-gallate
(-)epicatechin
-
IC50: 0.06 mM with 2-hydroxyestradiol as substrate, IC50: 0.08 mM with 4-hydroxyestradiol as substrate
(-)epicatechin gallate3,5-dinitrocatechol
-
with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(2-amino-3-methylbutanoyloxy)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
-
-
(2R,3R)-5,7-bis(acetyloxy)-2-[3,4,5-tris(acetyloxy)phenyl]-3,4-dihydro-2H-chromen-3-yl 3,4-bis(acetyloxy)-5-(2-oxopropyl)benzoate
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,4,5-trihydroxybenzoate)
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,5-dihydroxybenzoate)
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis[3,4,5-tris(acetyloxy)benzoate]
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis[3,5-bis(acetyloxy)benzoate]
-
-
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
1,2-dihydroxy-4-[2-(methylamino)butyl]benzene
-
uncompetitive inhibitor of the sCOMT isoform
1-(butyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
1-(isobutyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
1-Carboxysalsoline
-
i.e. 1-carboxy-1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, competitive inhibition of 3,4-dihydroxybenzoic acid methylation
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
-
-
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
-
-
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
-
-
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
1-[3,4-dihydroxy-5-nitrophenyl]-2-phenyl-ethanone
-
-
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
2-Hydroxyestradiol-17beta 3-methyl ether
-
product inhibition
2-hydroxyoestrogen
-
-
2-Iodosobenzoic acid
-
-
2-methoxyestradiol-17beta
-
product inhibition
3,4,5-trihydroxypyrogallol
-
liver homogenate, 0.03 mM inhibitior: 0.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
3,4-dihydroxymethamphetamine
-
uncompetitive inhibitor of the sCOMT isoform
3,5-dinitrocatechol
3-Carboxysalsolinol
-
-
3-chloro-5,6-dihydroxy-7-nitro-1-benzothiophene-2-carboxylic acid
-
-
3-fluoro-4-[1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]benzene-1,2-diol
-
liver homogenate, 0.03 mM inhibitior: 32.3% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
3-nitro-5-(1-p-tolyl-1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitior: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
3-nitro-5-(1-phenyl-1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitior: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
3-nitro-5-(1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitior: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
4''-O-methyl epigallocatechin gallate
-
potent inhibitor with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
4',3'',4''-tri-O-methyl epigallocatechin gallate
-
substrate: epigallocatechin
4',4''-di-O-methyl epigallocatechin gallate
-
potent inhibitor with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
4'-4''-di-O-methyl-epigallocatechin-3-gallate
-
IC50: 0.00015 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate, competitive with respect S-adenyosylmethionine, noncompetitive with respect to catechol
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methyl-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
-
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
-
4'-O-methyl-(-)-epigallocatechin
-
IC50: 0.032 mM with 2-hydroxyestradiol as substrate, IC50: 0.04 mM with 4-hydroxyestradiol as substrate
4'-O-methyl-epigallocatechin-3-gallate
-
IC50: 0.0001 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate
4-(1-phenyl-1H-pyrazol-5-yl)benzene-1,2,3-triol
-
liver homogenate, 0.03 mM inhibitior: 26.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
4-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-pyrazol-1-yl)benzonitrile
-
liver homogenate, 0.003 mM inhibitior: 0.3% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
4-(tert-octyl)phenol
-
causes significant inhibition of enzyme activity
4-hydroxyequilenin
-
inhibits its own methylation by COMT at higher concentrations in the presence of the reducing agent dithiothreitol, irreversible inhibitor, the inhibitor causes formation of intermolecular disulfide bonds, cys33 in recombinant human soluble COMT is the residue most likely modified by the inhibitor
4-nitrocatechol
-
-
4-phenyl-7,8-dihydroxycoumarin
-
-
4-[1-(4-methylphenyl)-1H-pyrazol-5-yl]benzene-1,2-diol
-
liver homogenate, 0.03 mM inhibitior: 41.2% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
4-[4-(4-chlorophenyl)-5-methyl-1H-pyrazol-3-yl]benzene-1,2,3-triol
-
liver homogenate, 0.003 mM inhibitior: 15.6% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
5-(1-methyl-1H-pyrazol-5-yl)-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitior: 1.1% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
5-Substituted 3-hydroxy-4-methoxybenzaldehydes
-
-
5-Substituted 3-hydroxy-4-methoxybenzoic acids
-
-
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
-
-
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
-
-
5-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-2,3-dihydroxybenzoic acid
-
liver homogenate, 0.03 mM inhibitior: 24.1% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
5-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitior: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
5-[1-(3-chlorophenyl)-4-phenyl-1H-pyrazol-5-yl]-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitior: 68.6% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
-
-
9-[(5E)-3,5,6,7-tetradeoxy-3-fluoro-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-xylo-hept-5-enofuranosyl]-N6-methyladenine
-
9-[(5E)-3,5,6,7-tetradeoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-3-methyl-beta-D-xylo-hept-5-enofuranosyl]-N6-propyladenine
-
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
-
-
Amino group reagents
-
-
-
Analogs of S-adenosyl-L-homocysteine
-
overview: inhibition of the liver, heart and brain enzyme
ascorbic acid
-
-
benzyl butyl phthalate
-
causes significant inhibition of enzyme activity
benzyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
beta-thujaplicin
-
70-100% inhibition at 0.2 mM
butyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
butyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
caffeic acid
caffeic acid phenethyl ester
-
COMT from liver, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37C; COMT from liver, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37C
catechin
catechol
-
-
CGP 28014
-
-
chlorogenic acid
-
COMT from liver, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37C; COMT from liver, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37C; COMT from placenta, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37C; COMT from placenta, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37C
chrysin
-
slight inhibition at 0.3 mM
Cistus parviflorus leaf extract
-
mixed type inhibition
-
daidzein
-
soy isoflavones at hormonally active concentrations cause a significant reduction of both COMT mRNA levels and COMT activity as well as of the methylation of 4-hydroxyestradiol
dibutyl phthalate
-
causes significant inhibition of enzyme activity
dihydromyricetin
-
competitive
diisononyl phthalate
-
causes significant inhibition of enzyme activity
dioctyl phthalate
-
causes significant inhibition of enzyme activity
dobutamine
-
competitive to dopamine
dopamine
-
competitive to dobutamine
entacapone
-
-
epicatechin
epigallocatechin
epigallocatechin-3-gallate
-
inhibition in vitro. Supplementation with a high dose does not impair the activity of COMT
Fe3+
-
quantum mechanical/molecular mechanical dynamics study
fisetin
flavone
-
IC50: 0.00549 mM
flavonoids
-
overview: relationship between structure and ability to inhibit
gallic acid
Gallic acid methylester
-
-
genistein
Hg2+
-
complete inhibition at 1 mM
High ionic strength
-
-
-
homocysteine
-
-
iodoacetamide
-
slight
iodoacetic acid
isobutyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
isopropyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
L-ascorbic acid
L-Dopa
methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
myricetin
-
competitive
Myricitrin
-
competitive
N-(2-[2-[(2R,3S,4R,5R)-5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-ethoxy]-ethyl)-2,3-dihydroxy-5-nitro-benzamide
-
IC50: 0.002 mM
N-(3,4-Dihydroxyphenyl)maleimide
-
irreversible
N-(3,4-Dihydroxyphenyl)succinimide
-
reversible
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
-
N-ethyl-3,4-dihydroxyamphetamine
-
uncompetitive inhibitor of the sCOMT isoform
N-ethylmaleimide
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
-
-
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
-
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(propylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-ethyl-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(cyclopropylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(ethylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
N-[(2E)-3-[(2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
N-[(E)-4-[(2R,3S,4R,5R)-5-(6-Amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-but-2-enyl]-2,3-dihydroxy-5-nitro-benzamide
-
IC50: 9 nM
N-[2-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]ethyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 60 nM
N-[3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]propyl]2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 200 nM
N-[4-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]butyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 0.005 mM
N-[[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 0.09 mM, very potent bisubstrate inhibitor
N6-methyl-9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]adenine
-
-
nebicapone
-
-
nitecapone
-
-
nordihydroguaiaretic acid
-
-
norepinephrine
-
0.01 mM, 41% inhibition of 2-hydroxyestradiol methylation
OR-462
-
disubstituted catechol
OR486
-
depressed COMT activity results in enhanced mechanical and thermal pain sensitivity
p-chloromercuribenzoate
p-hydroxymercuribenzoate
-
70-100% inhibition at 0.2 mM
Peganum harmala seed extract
-
mixed type inhibition
-
Phenolic compounds
-
-
-
Polyphenolic compounds
-
-
-
propyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
Purpurogallin
purpurogallin carboxylic acid
-
-
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
-
-
pyrogallol
quercetin
Ro 41-0960
RO-4-4602
-
competitive
Ro41-0960
S-adenosyl-L-homocysteine
S-adenosyl-L-methionine
-
-
Salsolidine
salvianolic acid B
-
weak inhibitor. In vivo, a single intravenous dose of salvianolic acid B decreases the plasma concentration of 3-O-methyldopa, with no obvious effect on the pharmacokinetics of L-dopa
-
theaflavin-3,3'-digallate
-
decreased Vmax and increased Km-value
tolcapone
Triton X-100
-
-
tropolone
U-0521
Vitex agnus-cactus leaf extract
-
mixed type inhibition
-
[5-(3,4-dihydroxy-5-nitrophenyl)-4-phenyl-1H-pyrazol-1-yl](4-methylphenyl)methanone
-
liver homogenate, 0.003 mM inhibitior: 2.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37C
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
cysteine
additional information
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0022 - 0.0082
(-)-epicatechin
-
-
0.0039 - 0.0067
(-)-epigallocatechin
-
-
0.02
(R)-1,2-dihydroxy-4-[2-(methylamino)butyl]benzene
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.03
(R)-3,4-dihydroxymethamphetamine
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.09
(R)-N-ethyl-3,4-dihydroxyamphetamine
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.02
(S)-1,2-dihydroxy-4-[2-(methylamino)butyl]benzene
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.03
(S)-3,4-dihydroxymethamphetamine
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.07
(S)-N-ethyl-3,4-dihydroxyamphetamine
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.000148 - 0.0175
2-hydroxyestradiol
0.014
2-hydroxyestradiol-17beta
-
-
0.64
3,4-dihydroxyphenylacetic acid
-
-
0.0024
4-hydroxyequilenin
-
pH 7.8
0.00037 - 0.0161
4-hydroxyestradiol
0.5
6,7-dihydroxycoumarin
-
-
0.0014 - 0.48
adrenaline
0.0064
aesculetin
-
pH 7.4, 37C
0.0022 - 0.0089
catechin
0.00836 - 0.833
catechol
0.0006
Catecholestradiol
-
-
0.0012
Catecholestrone
-
-
0.05
dobutamine
-
-
0.0005 - 0.44
dopamine
0.0043 - 0.0257
epicatechin
0.0081 - 0.0117
epigallocatechin
0.00017 - 0.0048
epigallocatechin gallate
0.0009 - 1
epinephrine
0.0062
esculetin
-
-
0.0015
fisetin
-
S-COMT, 0.25 mM S-adenosyl-L-methionine
0.00091 - 0.121
isoproterenol
0.266 - 0.613
levodopa
0.0055 - 1.856
norepinephrine
0.0038
p-nitrocatechol
-
-
0.0015 - 0.0069
quercetin
0.043 - 0.156
R-salsolinol
0.0031 - 0.6
S-adenosyl-L-methionine
0.0113 - 0.0797
salvianolic acid B
additional information
additional information
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.085 - 0.99
2-hydroxyestradiol
0.1
4-hydroxyequilenin
Homo sapiens
-
pH 7.8
0.035 - 0.077
4-hydroxyestradiol
0.18 - 0.26
catechin
9.67
catechol
Solanum lycopersicum
-
pH 7.5, 25C
0.088 - 0.19
dopamine
0.17 - 0.315
epicatechin
0.085 - 0.25
epinephrine
0.04 - 0.18
norepinephrine
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00032 - 0.00037
(-)-epigallocatechin-3-gallate
0.000006
(2-amino-3-methylbutanoyloxy)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.007022
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0000016
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000166
1-(butyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.000017
1-(isobutyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.44
1-Carboxysalsoline
-
-
0.004645
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.014
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0749
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000019
1-[3,4-dihydroxy-5-nitrophenyl]-2-phenyl-ethanone
-
-
0.0000456
3,5-dinitrocatechol
-
pH 7.4, 37C
0.000001
3-chloro-5,6-dihydroxy-7-nitro-1-benzothiophene-2-carboxylic acid
-
Ki value below 0.000001 mM, pH not specified in the publication, temperature not specified in the publication
0.026
4-hydroxyequilenin
-
pH 7.8, inhibition og methylation of 4-hydroxyestradiol
0.0024
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.002378
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000001
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000034
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0000102
benzyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000013
butyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000106
butyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0009
dihydromyricetin
-
37C, pH not specified in the publication
0.0003
entacapone
-
-
0.224
homocysteine
-
-
0.000017
isobutyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000011
isopropyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000022
methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0002
myricetin
-
37C, pH not specified in the publication
0.0005
Myricitrin
-
37C, pH not specified in the publication
0.0104
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0156
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0199
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000002
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000007
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
0.00102
nitecapone
-
-
0.0000092
propyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.07
Purpurogallin
-
-
0.000132
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0053 - 0.009
RO-4-4602
0.001 - 0.04
S-adenosyl-L-homocysteine
0.19
Salsolidine
-
-
0.0021
salvianolic acid B
-
37C, pH not specified in the publication
-
0.00027
tolcapone
-
-
0.005
tropolone
-
plus dopamine
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0003
(-)-epicatechin-3-gallate
Homo sapiens
-
IC50: 0.0002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0003 mM with 4-hydroxyestradiol as substrate
0.044 - 0.05
(-)-epigallocatechin
0.00007 - 0.00008
(-)-epigallocatechin-3-gallate
0.0025
(-)-epigallocatechin-3-gallate-3''-O-glucuronide
Homo sapiens
-
IC50: 0.002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0025 mM with 4-hydroxyestradiol as substrate
0.0023
(-)-epigallocatechin-3-gallate-3'-O-glucuronide
Homo sapiens
-
IC50: 0.0018 mM with 2-hydroxyestradiol as substrate, IC50: 0.0023 mM with 4-hydroxyestradiol as substrate
0.004
(-)-epigallocatechin-3-gallate-4''-O-glucuronide
Homo sapiens
-
IC50: 0.0025 mM with 2-hydroxyestradiol as substrate, IC50: 0.004 mM with 4-hydroxyestradiol as substrate
0.0006 - 0.0008
(-)-epigallocatechin-3-gallate-7-O-glucuronide
0.00004 - 0.0017
(-)-epigallocatechin-3-O-gallate
0.08
(-)epicatechin
Homo sapiens
-
IC50: 0.06 mM with 2-hydroxyestradiol as substrate, IC50: 0.08 mM with 4-hydroxyestradiol as substrate
0.0316
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.029
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,5-dihydroxybenzoate)
Homo sapiens
-
70-79% inhibition at 0.025-0.05 mM
0.3
1,2-dihydroxy-4-[2-(methylamino)butyl]benzene
Homo sapiens
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.0209
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0628
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.336
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0000265 - 0.000881
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
0.0000274 - 0.000237
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
0.2
3,4-dihydroxymethamphetamine
Homo sapiens
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.00004418
3,5-dinitrocatechol
Sus scrofa domesticus
-
pH 7.4, 37C
0.00015
4'-4''-di-O-methyl-epigallocatechin-3-gallate
Homo sapiens
-
IC50: 0.00015 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate, competitive with respect S-adenyosylmethionine, noncompetitive with respect to catechol
0.001368
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methyl-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.001858
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.04
4'-O-methyl-(-)-epigallocatechin
Homo sapiens
-
IC50: 0.032 mM with 2-hydroxyestradiol as substrate, IC50: 0.04 mM with 4-hydroxyestradiol as substrate
0.0001
4'-O-methyl-epigallocatechin-3-gallate
Homo sapiens
-
IC50: 0.0001 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate
0.000013 - 0.000565
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
0.0108
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0107
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000006
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000011
9-[(5E)-3,5,6,7-tetradeoxy-3-fluoro-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-xylo-hept-5-enofuranosyl]-N6-methyladenine
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000025
9-[(5E)-3,5,6,7-tetradeoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-3-methyl-beta-D-xylo-hept-5-enofuranosyl]-N6-propyladenine
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000155
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.00164 - 0.019
catechin
0.00196 - 0.068
epicatechin
0.006 - 0.048
epigallocatechin
0.0021 - 0.0045
fisetin
0.00549
flavone
Homo sapiens
-
IC50: 0.00549 mM
0.00457
Harmaline
Sus scrofa domesticus
-
pH 7.4, 37C
0.01319
harmalol
Sus scrofa domesticus
-
pH 7.4, 37C
0.002
N-(2-[2-[(2R,3S,4R,5R)-5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-ethoxy]-ethyl)-2,3-dihydroxy-5-nitro-benzamide
Homo sapiens
-
IC50: 0.002 mM
0.0468
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.1
N-ethyl-3,4-dihydroxyamphetamine
Homo sapiens
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.0703
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.0895
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000011
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000026
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(propylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000009
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
0.000031 - 0.000035
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
0.000236
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-ethyl-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000082
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(cyclopropylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000043
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(ethylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.028
N-[(2E)-3-[(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.00004
N-[(2E)-3-[(2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
P22734
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000009
N-[(E)-4-[(2R,3S,4R,5R)-5-(6-Amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-but-2-enyl]-2,3-dihydroxy-5-nitro-benzamide
Homo sapiens
-
IC50: 9 nM
0.00006
N-[2-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]ethyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
Homo sapiens
-
IC50: 60 nM
0.0002
N-[3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]propyl]2,3-dihydroxy-5-nitrobenzene-1-carboxamide
Homo sapiens
-
IC50: 200 nM
0.005
N-[4-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]butyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
Homo sapiens
-
IC50: 0.005 mM
0.09
N-[[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
Homo sapiens
-
IC50: 0.09 mM, very potent bisubstrate inhibitor
0.000032
N6-methyl-9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]adenine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.000596
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37C
0.00048 - 0.0085
quercetin
0.000005 - 0.000042
Ro 41-0960
Homo sapiens
-
IC50: 5-42 nM
0.0000067
tolcapone
Homo sapiens
-
isoform MB-COMT, pH 7.4, 37C
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.00107
-
pH 7.4, 37C
additional information